Sickle Cell Disease Clinical Trials

 

St. Jude Clinical Trials

EPSTRV: Retroviral Vector Mediated Globin Gene Transfer to Correct Sickle Cell Anemia or Thalassemia

Diseases Treated:

Sickle cell anemia

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant’s age is equal to or greater than two (2) years old
  • No active sickle cell disease
  • Adequate blood counts
View Trial

INSIGHT-HD: Investigating the Genetics of Hematologic Diseases

Diseases Treated:

Non-malignant blood diseases (non-therapeutic)

Eligibility:

  • Receiving therapy or a consultation for a non-malignant blood disorder
  • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
View Trial

MEMREAD: Working Memory and School Readiness in Preschool-aged Children with Sickle Cell Disease: Family and Environmental Factors

Diseases Treated:

Sickle cell disease

Eligibility:

This is a non-therapeutic clinical trial open to St. Jude patients only.

View Trial

MIDAS: Massive Iron Overload Assessment

Diseases Treated:

Iron overload 

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant has a history of 12 or more lifetime erythrocyte transfusions.
  • Participant has a need for liver iron content assessment.
  • No contra-indication to having an MRI exam, such as the presence of metal in the body.
View Trial

PMVOC: Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease

Diseases Treated:

Sickle cell disease

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

View Trial

SCCRIP: Sickle Cell Research and Intervention Program

Diseases Treated:

Sickle cell disease

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.
  • Participant has a diagnosis of Sickle Cell Disease of any genotype.
View Trial

Collaborative Clinical Trials

NOTCHES1: Novel Therapies in Children with Sickle Cell Disease

Diseases Treated:

Sickle cell disease

Eligibility:

  • 12 to 17 years old
  • Diagnosis of sickle cell disease
  • Able to swallow capsules

 

View Trial

TADO: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Diseases Treated:

Sickle cell disease

Eligibility:

  • Participant with Sickle Cell Disease (laboratory determined HbSS or HbS beta zero thalassemia) who have had >2 episodes of Vaso-occlusive crisis in the past year. 
  • Participants >2 years of age and < 18 years of age.
View Trial